Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on October 27, 2015. The registrant is a Delaware corporation headquartered in San Diego, California. The filing reports a specific corporate event rather than periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is an event-driven report and does not contain financial statements or quantitative financial data.
Material Changes
The material event reported is the presentation of clinical data regarding the Company's Precision Cancer Monitoring (PCM) platform. Specifically, the data features the quantitative detection and monitoring of EGFR T790M mutations in patients diagnosed with non-small cell lung cancer.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) detailing the clinical data presentation. No specific financial guidance, forward-looking projections, or explicit risk factors are detailed within the text of this Form 8-K summary.
Investor Verification Checklist
- Verify the full content of the press release attached as Exhibit 99.1 for detailed clinical trial results.
- Confirm the specific conference or venue where the EGFR T790M mutation data was presented.
- Review the Company's most recent 10-K or 10-Q filings for actual financial performance metrics, as this 8-K contains none.
- Note the discrepancy in the request metadata: the filing is for Trovagene, Inc., not Cardiff Oncology, Inc.